Alexandru Sircuta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandru Sircuta has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Flaviu Bob
Division of Nephrology, Department of Internal Medicine II, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania
8 shared publications - Iulia Grosu
Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, Romania
8 shared publications - Adalbert Schiller
Centre for Molecular Research in Nephrology and Vascular Disease/MOL-NEPHRO-VASC, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
7 shared publications - Ligia Petrica
Centre for Cognitive Research in Neuropsychiatric Pathology (NeuroPsy-Cog), Department of Neurosciences, Victor Babes University of Medicine and Pharmacy, 156 L. Rebreanu Ave., 300736 Timisoara, Romania
7 shared publications - Marcel Palamar
Department of Internal Medicine II—Nephrology University Clinic, “Victor Babeș” University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timișoara, Romania
5 shared publications - Maria Daniela Tanasescu
Nephrology Department, Bucharest Emergency University Hospital, 050098 Bucharest, Romania
5 shared publications
Latest Publications
- Open Access
Vascular Calcification in Chronic Kidney Disease and Hemodialysis: Pathophysiological Mechanisms and Emerging Biomarkers
Background and Objectives: Vascular calcification (VC) is a major contributor to cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD), particularly those on hemodialysis. Once considered a passive process, VC is now recognized as an active, cell-mediated pathology influenced by mineral dysregulation, chronic inflammation, and oxidative stress. This review aims to synthesize current evidence on the underlying mechanisms of VC in CKD and hemodialysis, with particular focus on emerging biomarkers and therapeutic implications. Materials and Methods: A structured narrative review was conducted by searching PubMed, Web of Science, ScienceDirect, and Google Scholar. The final search was completed on 29 August 2025. A total of 1326 articles were initially retrieved, of which 65 met the inclusion criteria and were analyzed. Studies addressing VC mechanisms, the bone–vascular axis, mineral metabolism, vitamin K–dependent proteins, and biomarkers such as matrix Gla protein (MGP), osteocalcin (OC), and intact parathyroid hormone (iPTH) were included. Results: VC in CKD arises from phenotypic transformation of vascular smooth muscle cells, vesicle-mediated calcification, oxidative stress, and impaired activity of endogenous calcification inhibitors. Disruption of the fibroblast growth factor 23 (FGF23)–Klotho axis and secondary hyperparathyroidism further exacerbate vascular pathology. Among emerging biomarkers, dp-ucMGP reflects vitamin K deficiency and correlates with calcification burden, while OC and iPTH provide insight into bone–vascular crosstalk and mineral turnover. However, biomarker interpretation is limited by assay variability, renal clearance, and clinical heterogeneity. Conclusions: VC in CKD represents a complex process driven by systemic and cellular dysregulation. While biomarkers such as dp-ucMGP, OC, and iPTH offer mechanistic insights and prognostic potential, further validation is required for clinical application. A multimarker approach, combined with individualized management of mineral metabolism, may improve risk stratification and therapeutic targeting in this high-risk population.
Open AccessVascular Calcification in Chronic Kidney Disease and Hemodialysis: Pathophysiological Mechanisms and Emerging Biomarkers
Background and Objectives: Vascular calcification (VC) is a major contributor to cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD), particularly those on hemodialysis. Once considered a passive process, VC is now recognized as an active, cell-mediated pathology influenced by mineral dysregulation, chronic inflammation, and oxidative stress. This review aims to synthesize current evidence on the underlying mechanisms of VC in CKD and hemodialysis, with particular focus on emerging biomarkers and therapeutic implications. Materials and Methods: A structured narrative review was conducted by searching PubMed, Web of Science, ScienceDirect, and Google Scholar. The final search was completed on 29 August 2025. A total of 1326 articles were initially retrieved, of which 65 met the inclusion criteria and were analyzed. Studies addressing VC mechanisms, the bone–vascular axis, mineral metabolism, vitamin K–dependent proteins, and biomarkers such as matrix Gla protein (MGP), osteocalcin (OC), and intact parathyroid hormone (iPTH) were included. Results: VC in CKD arises from phenotypic transformation of vascular smooth muscle cells, vesicle-mediated calcification, oxidative stress, and impaired activity of endogenous calcification inhibitors. Disruption of the fibroblast growth factor 23 (FGF23)–Klotho axis and secondary hyperparathyroidism further exacerbate vascular pathology. Among emerging biomarkers, dp-ucMGP reflects vitamin K deficiency and correlates with calcification burden, while OC and iPTH provide insight into bone–vascular crosstalk and mineral turnover. However, biomarker interpretation is limited by assay variability, renal clearance, and clinical heterogeneity. Conclusions: VC in CKD represents a complex process driven by systemic and cellular dysregulation. While biomarkers such as dp-ucMGP, OC, and iPTH offer mechanistic insights and prognostic potential, further validation is required for clinical application. A multimarker approach, combined with individualized management of mineral metabolism, may improve risk stratification and therapeutic targeting in this high-risk population.
- Open Access
IL-6 Versus TNF-α as Predictors of Echocardiographic Cardiac Remodeling in Maintenance Hemodialysis Patients
Background and Objectives: Cardiovascular disease remains the leading cause of mortality in end-stage renal disease, with systemic inflammation implicated in myocardial remodeling. We aimed to assess the associations between IL-6, TNF-α, and IL-1β and echocardiographic parameters of cardiac remodeling, including left ventricular mass (LVM), global longitudinal strain (GLS), interventricular septum (IVS), left ventricular end-diastolic diameter (LVEDD), and right ventricular diameter (RVD), in patients undergoing maintenance hemodialysis. This was a single-center retrospective observational study. Materials and Methods: In 58 maintenance hemodialysis patients (mean age 60.4 ± 11.7 years; 55% male), pre-dialysis serum cytokines (IL-6, TNF-α, IL-1β) and standard laboratory markers (C-reactive protein [CRP], albumin, hemoglobin) were measured. Echocardiography was performed under clinically stable conditions. Spearman correlations assessed relationships between cytokines and imaging parameters; multivariate linear regression identified independent predictors. Results: Median IL-6 was 7.36 pg/mL (interquartile range [IQR] 4.52–11.03), and median TNF-α was 9.35 pg/mL (IQR 7.9–12.57). IL-6 correlated positively with LVM (ρ = 0.63, p < 0.001), RVD (ρ = 0.53, p < 0.001), and CRP (ρ = 0.52, p < 0.001). In contrast, TNF-α inversely correlated with LVM (ρ = −0.36, p = 0.006). Multivariate regression showed IL-6 was independently predicted by LVM (p = 0.019) and RVD (p = 0.042), while TNF-α was predicted by age (p < 0.001), CRP (p = 0.038), and albumin (p = 0.012). Conclusions: In hemodialysis patients, IL-6 showed stronger associations with echocardiographic hypertrophy and dilation than TNF-α, supporting its role as a potential biomarker of subclinical cardiac remodeling.IL-6 showed stronger correlations with echocardiographic remodeling markers compared with TNF-α and may warrant further investigation as a potential biomarker in this setting.
Open AccessIL-6 Versus TNF-α as Predictors of Echocardiographic Cardiac Remodeling in Maintenance Hemodialysis Patients
Background and Objectives: Cardiovascular disease remains the leading cause of mortality in end-stage renal disease, with systemic inflammation implicated in myocardial remodeling. We aimed to assess the associations between IL-6, TNF-α, and IL-1β and echocardiographic parameters of cardiac remodeling, including left ventricular mass (LVM), global longitudinal strain (GLS), interventricular septum (IVS), left ventricular end-diastolic diameter (LVEDD), and right ventricular diameter (RVD), in patients undergoing maintenance hemodialysis. This was a single-center retrospective observational study. Materials and Methods: In 58 maintenance hemodialysis patients (mean age 60.4 ± 11.7 years; 55% male), pre-dialysis serum cytokines (IL-6, TNF-α, IL-1β) and standard laboratory markers (C-reactive protein [CRP], albumin, hemoglobin) were measured. Echocardiography was performed under clinically stable conditions. Spearman correlations assessed relationships between cytokines and imaging parameters; multivariate linear regression identified independent predictors. Results: Median IL-6 was 7.36 pg/mL (interquartile range [IQR] 4.52–11.03), and median TNF-α was 9.35 pg/mL (IQR 7.9–12.57). IL-6 correlated positively with LVM (ρ = 0.63, p < 0.001), RVD (ρ = 0.53, p < 0.001), and CRP (ρ = 0.52, p < 0.001). In contrast, TNF-α inversely correlated with LVM (ρ = −0.36, p = 0.006). Multivariate regression showed IL-6 was independently predicted by LVM (p = 0.019) and RVD (p = 0.042), while TNF-α was predicted by age (p < 0.001), CRP (p = 0.038), and albumin (p = 0.012). Conclusions: In hemodialysis patients, IL-6 showed stronger associations with echocardiographic hypertrophy and dilation than TNF-α, supporting its role as a potential biomarker of subclinical cardiac remodeling.IL-6 showed stronger correlations with echocardiographic remodeling markers compared with TNF-α and may warrant further investigation as a potential biomarker in this setting.
- Open Access
- 2 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (17) , 9654
Elevated Parathyroid Hormone Levels Are Associated with Increased Risk of Arteriovenous Fistula Thrombosis in Hemodialysis Patients: Findings from a 5-Year Cohort Study
(1) Background: Arteriovenous fistula (AVF) thrombosis represents a major cause of vascular access failure in patients undergoing maintenance hemodialysis. Identifying early biochemical markers associated with thrombosis may facilitate timely intervention and improve vascular outcomes. This study aimed to evaluate the association between baseline biochemical markers and the risk of AVF thrombosis and mortality during long-term follow-up. (2) Methods: We conducted a prospective observational study involving 249 chronic hemodialysis patients with functional AVFs. Baseline data included intact parathyroid hormone (iPTH), hemoglobin, phosphate, potassium, albumin, dialysis adequacy (Kt/V), age, diabetes status, and antivitamin K (AVK) therapy. Patients were followed for five years for the occurrence of AVF thrombosis and mortality. Statistical analysis was performed using one-way ANOVA with Levene’s test and Scheffé post hoc comparisons. (3) Results: iPTH levels were significantly higher in patients who developed AVF thrombosis (mean 494.6 pg/mL) than in those without thrombosis (mean 381.5 pg/mL; p = 0.047). Other variables, including hemoglobin, phosphate, Kt/V, age, diabetes, and AVK therapy, were not significantly associated with thrombosis. Mortality was more frequent among patients with diabetes mellitus and those receiving antivitamin K therapy; however, only the association with diabetes reached statistical significance. (4) Conclusions: Elevated iPTH was associated with AVF thrombosis. Routine monitoring may help identify high-risk patients and guide timely interventions.
- 2 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (17) , 9654
Open AccessElevated Parathyroid Hormone Levels Are Associated with Increased Risk of Arteriovenous Fistula Thrombosis in Hemodialysis Patients: Findings from a 5-Year Cohort Study
(1) Background: Arteriovenous fistula (AVF) thrombosis represents a major cause of vascular access failure in patients undergoing maintenance hemodialysis. Identifying early biochemical markers associated with thrombosis may facilitate timely intervention and improve vascular outcomes. This study aimed to evaluate the association between baseline biochemical markers and the risk of AVF thrombosis and mortality during long-term follow-up. (2) Methods: We conducted a prospective observational study involving 249 chronic hemodialysis patients with functional AVFs. Baseline data included intact parathyroid hormone (iPTH), hemoglobin, phosphate, potassium, albumin, dialysis adequacy (Kt/V), age, diabetes status, and antivitamin K (AVK) therapy. Patients were followed for five years for the occurrence of AVF thrombosis and mortality. Statistical analysis was performed using one-way ANOVA with Levene’s test and Scheffé post hoc comparisons. (3) Results: iPTH levels were significantly higher in patients who developed AVF thrombosis (mean 494.6 pg/mL) than in those without thrombosis (mean 381.5 pg/mL; p = 0.047). Other variables, including hemoglobin, phosphate, Kt/V, age, diabetes, and AVK therapy, were not significantly associated with thrombosis. Mortality was more frequent among patients with diabetes mellitus and those receiving antivitamin K therapy; however, only the association with diabetes reached statistical significance. (4) Conclusions: Elevated iPTH was associated with AVF thrombosis. Routine monitoring may help identify high-risk patients and guide timely interventions.
- Open Access
- 10 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1163
Associations Between Inflammatory and Bone Turnover Markers and Mortality in Hemodialysis Patients
Background/Objectives: Chronic kidney disease–mineral and bone disorder (CKD-MBD) and systemic inflammation contribute to mortality in hemodialysis (HD) patients. The primary aim of this study was to determine whether specific CKD-MBD markers and inflammatory biomarkers are associated with increased mortality risk in HD patients. Methods: We conducted a retrospective cohort study on 63 stage 5D CKD patients undergoing maintenance HD. Serum intact parathyroid hormone (iPTH), soluble Klotho, calcium, phosphorus, 25(OH)D (25-hydroxyvitamin D), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), C-reactive protein (CRP), and interleukin-6 (IL-6) were analyzed. A Cox regression analysis assessed mortality predictors, and linear regression analysis evaluated CKD-MBD–inflammation correlations. Results: Lower iPTH (p = 0.042). Other CKD-MBD markers (calcium, phosphorus, 25(OH)D, VEGF, TGF-β) did not impact survival. Soluble Klotho correlated positively with IL-6 (r = 0.57, p < 0.001), suggesting a compensatory inflammatory response. Conclusions: Our findings demonstrate that low iPTH levels and advanced age are independent predictors of mortality in hemodialysis patients. The positive association between soluble Klotho and IL-6 suggests a potential compensatory inflammatory response. These results highlight the need for further research to clarify underlying mechanisms and to explore novel therapeutic strategies.
- 10 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1163
Open AccessAssociations Between Inflammatory and Bone Turnover Markers and Mortality in Hemodialysis Patients
Background/Objectives: Chronic kidney disease–mineral and bone disorder (CKD-MBD) and systemic inflammation contribute to mortality in hemodialysis (HD) patients. The primary aim of this study was to determine whether specific CKD-MBD markers and inflammatory biomarkers are associated with increased mortality risk in HD patients. Methods: We conducted a retrospective cohort study on 63 stage 5D CKD patients undergoing maintenance HD. Serum intact parathyroid hormone (iPTH), soluble Klotho, calcium, phosphorus, 25(OH)D (25-hydroxyvitamin D), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), C-reactive protein (CRP), and interleukin-6 (IL-6) were analyzed. A Cox regression analysis assessed mortality predictors, and linear regression analysis evaluated CKD-MBD–inflammation correlations. Results: Lower iPTH (p = 0.042). Other CKD-MBD markers (calcium, phosphorus, 25(OH)D, VEGF, TGF-β) did not impact survival. Soluble Klotho correlated positively with IL-6 (r = 0.57, p < 0.001), suggesting a compensatory inflammatory response. Conclusions: Our findings demonstrate that low iPTH levels and advanced age are independent predictors of mortality in hemodialysis patients. The positive association between soluble Klotho and IL-6 suggests a potential compensatory inflammatory response. These results highlight the need for further research to clarify underlying mechanisms and to explore novel therapeutic strategies.
- Open Access
- 28 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 48
Vitamin K-Dependent Proteins as Predictors of Valvular Calcifications and Mortality in Hemodialysis Patients
Background/Objectives: Vitamin K deficiency in chronic kidney disease (CKD) could potentially occur due to multiple factors, leading to an increased risk of vascular and valvular calcifications. Vitamin K status can be indirectly assessed by measuring the blood levels of vitamin K-dependent proteins (VKDPs), such as matrix GLA protein (MGP). This study aims to examine the relationship between the levels of inactive MGP (dp-uc MGP) and the presence of valvular calcifications, as well as its association with mortality in hemodialysis patients. Methods: We conducted a single-center study that included 45 CKD G5D patients (hemodialysis for 6 months to 10 years) followed up for 24 months. All patients have been assessed at baseline regarding cardiovascular disease (medical history, echocardiography). Moreover, using standard methods, we determined blood biochemistry, complete blood count, and matrix GLA protein. At 24 months of follow-up, we assessed all-cause mortality and cardiovascular mortality. Results: In the studied hemodialysis patients, mean dp-uc MGP was 3285.93 +/− 2092.85 pmol/L. Patients with valvular calcifications had higher levels of dp-uc MGP compared to those without (4521.08 +/− 2263.82 vs. 2487.53 +/− 1446.94 pmol/L, however not statistically significant). The presence and severity of valvular calcifications were significantly associated with the history of treatment with vitamin K antagonists (p < 0.05). After 24 months of follow-up, we found an all-cause mortality rate of 24.4%. The level of dp-uc MGP was higher in the group of patients that died (3884.81 +/− 2439.20 vs. 3133.09 +/− 1925.26 pmol/L, p > 0.05). Patients with more than one valvular calcification on echocardiography had a significantly higher all-cause mortality risk (p = 0.04). In terms of traditional risk factors, we observed an increased risk of all-cause mortality in patients with a history of diabetes mellitus (p = 0.02) and aortic stenosis (p = 0.01). However, other cardiovascular markers, such as coronary heart disease and ejection fraction < 50%, did not have a statistically significant impact on mortality in our patients. Conclusions: In our study, we found that vitamin K deficiency, measured indirectly using the level of VKDP, especially dp-uc MGP, is a predictor of valvular calcifications. Severe valvular calcifications, aortic stenosis, and the presence of diabetes mellitus are risk factors for all-cause mortality in hemodialysis patients.
- 28 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 48
Open AccessVitamin K-Dependent Proteins as Predictors of Valvular Calcifications and Mortality in Hemodialysis Patients
Background/Objectives: Vitamin K deficiency in chronic kidney disease (CKD) could potentially occur due to multiple factors, leading to an increased risk of vascular and valvular calcifications. Vitamin K status can be indirectly assessed by measuring the blood levels of vitamin K-dependent proteins (VKDPs), such as matrix GLA protein (MGP). This study aims to examine the relationship between the levels of inactive MGP (dp-uc MGP) and the presence of valvular calcifications, as well as its association with mortality in hemodialysis patients. Methods: We conducted a single-center study that included 45 CKD G5D patients (hemodialysis for 6 months to 10 years) followed up for 24 months. All patients have been assessed at baseline regarding cardiovascular disease (medical history, echocardiography). Moreover, using standard methods, we determined blood biochemistry, complete blood count, and matrix GLA protein. At 24 months of follow-up, we assessed all-cause mortality and cardiovascular mortality. Results: In the studied hemodialysis patients, mean dp-uc MGP was 3285.93 +/− 2092.85 pmol/L. Patients with valvular calcifications had higher levels of dp-uc MGP compared to those without (4521.08 +/− 2263.82 vs. 2487.53 +/− 1446.94 pmol/L, however not statistically significant). The presence and severity of valvular calcifications were significantly associated with the history of treatment with vitamin K antagonists (p < 0.05). After 24 months of follow-up, we found an all-cause mortality rate of 24.4%. The level of dp-uc MGP was higher in the group of patients that died (3884.81 +/− 2439.20 vs. 3133.09 +/− 1925.26 pmol/L, p > 0.05). Patients with more than one valvular calcification on echocardiography had a significantly higher all-cause mortality risk (p = 0.04). In terms of traditional risk factors, we observed an increased risk of all-cause mortality in patients with a history of diabetes mellitus (p = 0.02) and aortic stenosis (p = 0.01). However, other cardiovascular markers, such as coronary heart disease and ejection fraction < 50%, did not have a statistically significant impact on mortality in our patients. Conclusions: In our study, we found that vitamin K deficiency, measured indirectly using the level of VKDP, especially dp-uc MGP, is a predictor of valvular calcifications. Severe valvular calcifications, aortic stenosis, and the presence of diabetes mellitus are risk factors for all-cause mortality in hemodialysis patients.
- Open Access
- 20 August 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1903
The Relationship between Circulating Kidney Injury Molecule-1 and Cardiovascular Morbidity and Mortality in Hemodialysis Patients
Background: The importance of identifying mortality biomarkers in chronic kidney disease (CKD), and especially in patients treated with hemodialysis (HD), has become evident. In addition to being a marker of tubulointerstitial injury, plasma kidney injury molecule-1 (KIM-1) has been mentioned in regard to HD patients as a risk marker for cardiovascular (CV) mortality and coronary artery calcification. The aim of this study was to assess the level of plasma KIM-1 as a marker of cardiovascular disease (CVD) and mortality in CKD5-HD patients (patients with CKD stage G5D treated with hemodialysis). Methods: We conducted a prospective case–control study that included 63 CKD5-HD patients (HD for 1–5 years) followed up for 48 months and a control group consisting of 52 non-dialysis patients diagnosed with CKD stages G1-G5 (ND-CKD). All patients had a CVD baseline assessment including medical history, echocardiography, and electrocardiography (ECG). Circulating plasma KIM-1 levels were determined with single-molecule counting immunoassay technology using an enzyme-linked immunosorbent assay. We obtained the following parameters: serum creatinine and urea; the inflammation markers CRP (C-reactive protein) and IL-6 (interleukin-6); and the anemia markers complete blood count, serum ferritin, and transferrin saturation (TSAT). Results: The mean plasma KIM-1 level was 403.8 ± 546.8 pg/mL, showing a statistically significant correlation with inflammation (CRP, R = 0.28, p = 0.02; IL-6, R = 0.36, p = 0.005) and with anemia (hematocrit, R = −0.5, p = −0.0316; hemoglobin (Hb), R = −0.5, p = 0.02). We found that patients with left ventricular hypertrophy (LVH) on echocardiography (59.7%) had significantly lower mean levels of plasma KIM-1 than patients from the control group (155.51 vs. 432.12 pg/mL; p = 0.026). Regarding the patients’ follow-up, we assessed all-cause mortality as an endpoint. After 24 months of follow-up, we found a mortality rate of 22.23%, while after 48 months, the mortality rate was 50.73%. A plasma KIM-1 level < 82.98 pg/mL was significantly associated with decreased survival in hemodialysis patients (p < 0.001). Conclusions: In patients treated with hemodialysis, low levels of plasma KIM-1 were associated with cardiovascular changes and an increased risk of mortality. Plasma KIM-1 levels were significantly higher in HD patients compared to ND-CKD patients.
- 20 August 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1903
Open AccessThe Relationship between Circulating Kidney Injury Molecule-1 and Cardiovascular Morbidity and Mortality in Hemodialysis Patients
Background: The importance of identifying mortality biomarkers in chronic kidney disease (CKD), and especially in patients treated with hemodialysis (HD), has become evident. In addition to being a marker of tubulointerstitial injury, plasma kidney injury molecule-1 (KIM-1) has been mentioned in regard to HD patients as a risk marker for cardiovascular (CV) mortality and coronary artery calcification. The aim of this study was to assess the level of plasma KIM-1 as a marker of cardiovascular disease (CVD) and mortality in CKD5-HD patients (patients with CKD stage G5D treated with hemodialysis). Methods: We conducted a prospective case–control study that included 63 CKD5-HD patients (HD for 1–5 years) followed up for 48 months and a control group consisting of 52 non-dialysis patients diagnosed with CKD stages G1-G5 (ND-CKD). All patients had a CVD baseline assessment including medical history, echocardiography, and electrocardiography (ECG). Circulating plasma KIM-1 levels were determined with single-molecule counting immunoassay technology using an enzyme-linked immunosorbent assay. We obtained the following parameters: serum creatinine and urea; the inflammation markers CRP (C-reactive protein) and IL-6 (interleukin-6); and the anemia markers complete blood count, serum ferritin, and transferrin saturation (TSAT). Results: The mean plasma KIM-1 level was 403.8 ± 546.8 pg/mL, showing a statistically significant correlation with inflammation (CRP, R = 0.28, p = 0.02; IL-6, R = 0.36, p = 0.005) and with anemia (hematocrit, R = −0.5, p = −0.0316; hemoglobin (Hb), R = −0.5, p = 0.02). We found that patients with left ventricular hypertrophy (LVH) on echocardiography (59.7%) had significantly lower mean levels of plasma KIM-1 than patients from the control group (155.51 vs. 432.12 pg/mL; p = 0.026). Regarding the patients’ follow-up, we assessed all-cause mortality as an endpoint. After 24 months of follow-up, we found a mortality rate of 22.23%, while after 48 months, the mortality rate was 50.73%. A plasma KIM-1 level < 82.98 pg/mL was significantly associated with decreased survival in hemodialysis patients (p < 0.001). Conclusions: In patients treated with hemodialysis, low levels of plasma KIM-1 were associated with cardiovascular changes and an increased risk of mortality. Plasma KIM-1 levels were significantly higher in HD patients compared to ND-CKD patients.
- Open Access
- 3 October 2023
- Published by MDPI AG in Applied Sciences
- Vol. 13 (19) , 10938
Vitamin K Status of Patients Undergoing Hemodialysis: Insights from a Cross-Sectional Study
(1) Background: Vitamin K deficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and an increased risk of vascular calcifications. A method to indirectly assess the vitamin K status is measuring the blood level of vitamin K-dependent proteins (VKDP): osteocalcin (OC) and matrix GLA protein (MGP). The aim of this study is to correlate the level of total OC and inactive MGP (dp-uc MGP) with markers of CKD mineral bone disorder (CKD-MBD). (2) Methods: We conducted a single-center cross-sectional study that included 45 CKD G5D patients and measured their blood biochemistry, complete blood count and total osteocalcin and dp-uc MGP contents. (3) Results: We found a strong, statistically significant correlation of the total OC with the markers of CKD-MBD, such as: iPTH, serum calcium and serum phosphorus, and a strong, indirect statistically significant correlation with abdominal circumference. There was also a statistically significant correlation of dp-uc MGP with the markers of inflammation (CRP). Higher levels of dp-uc MGP were found in the patients treated with vitamin K antagonists, non-calcium-based phosphate binders and the vitamin D receptor activator, paricalcitol. (4) Conclusions: In our study, we found that when it is measured indirectly using VKDP levels, vitamin K deficiency is associated with CKD-MBD. Certain widely used medications such as phosphate binders reduce vitamin K absorption, supplementary vitamin D increases vitamin K requirements, and also vitamin K antagonists influence the blood level of VKDPs.
- 3 October 2023
- Published by MDPI AG in Applied Sciences
- Vol. 13 (19) , 10938
Open AccessVitamin K Status of Patients Undergoing Hemodialysis: Insights from a Cross-Sectional Study
(1) Background: Vitamin K deficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and an increased risk of vascular calcifications. A method to indirectly assess the vitamin K status is measuring the blood level of vitamin K-dependent proteins (VKDP): osteocalcin (OC) and matrix GLA protein (MGP). The aim of this study is to correlate the level of total OC and inactive MGP (dp-uc MGP) with markers of CKD mineral bone disorder (CKD-MBD). (2) Methods: We conducted a single-center cross-sectional study that included 45 CKD G5D patients and measured their blood biochemistry, complete blood count and total osteocalcin and dp-uc MGP contents. (3) Results: We found a strong, statistically significant correlation of the total OC with the markers of CKD-MBD, such as: iPTH, serum calcium and serum phosphorus, and a strong, indirect statistically significant correlation with abdominal circumference. There was also a statistically significant correlation of dp-uc MGP with the markers of inflammation (CRP). Higher levels of dp-uc MGP were found in the patients treated with vitamin K antagonists, non-calcium-based phosphate binders and the vitamin D receptor activator, paricalcitol. (4) Conclusions: In our study, we found that when it is measured indirectly using VKDP levels, vitamin K deficiency is associated with CKD-MBD. Certain widely used medications such as phosphate binders reduce vitamin K absorption, supplementary vitamin D increases vitamin K requirements, and also vitamin K antagonists influence the blood level of VKDPs.
- Open Access
- 22 August 2023
- Published by MDPI AG in Preprints.org
Factors Influencing Vitamin K Deficiency In Hemodialysis Patients
(1) Background: Vitamin K deficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and increased risk of vascular calcifications. A method to indirectly measure Vitamin K status is measuring the blood level of Vitamin K dependent proteins (VKDP)- osteocalcin (OC) and matrix GLA protein (MGP). The aim of this study is to correlate the level of OC and MGP with markers of CKD mineral bone disorder (CKD-MBD). (2) Methods: We conducted a single-center cross-sectional study that included 45 CKD G5D patients and measured blood biochemistry, complete blood count and intact osteocalcin and matrix GLA protein. (3) Results: We found a strong statistically significant correlation of OC with the markers of CKD-MBD such as: iPTH , serum calcium and serum phosphorus and a strong indirect statistically significant correlation with abdominal circumference. There was also a statistically significant correlation of MGP with markers of inflammation (CRP). Higher levels of MGP were found in patients treated with vitamin K antagonists, non-calcium based phosphate binders and vitamin D receptor activator- paricalcitol. (4) Conclusions: In our study, we found that vitamin K deficiency, measured indirectly using the level of VKDP is associated to CKD-MBD. The use of medication such as phosphate binders, that reduce vitamin K absorbtion, Vitamin D that increases Vitamin K requirements and also vitamin K antagonists, seem to have an influence on the blood level of VKDPs.
- 22 August 2023
- Published by MDPI AG in Preprints.org
Open AccessFactors Influencing Vitamin K Deficiency In Hemodialysis Patients
(1) Background: Vitamin K deficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and increased risk of vascular calcifications. A method to indirectly measure Vitamin K status is measuring the blood level of Vitamin K dependent proteins (VKDP)- osteocalcin (OC) and matrix GLA protein (MGP). The aim of this study is to correlate the level of OC and MGP with markers of CKD mineral bone disorder (CKD-MBD). (2) Methods: We conducted a single-center cross-sectional study that included 45 CKD G5D patients and measured blood biochemistry, complete blood count and intact osteocalcin and matrix GLA protein. (3) Results: We found a strong statistically significant correlation of OC with the markers of CKD-MBD such as: iPTH , serum calcium and serum phosphorus and a strong indirect statistically significant correlation with abdominal circumference. There was also a statistically significant correlation of MGP with markers of inflammation (CRP). Higher levels of MGP were found in patients treated with vitamin K antagonists, non-calcium based phosphate binders and vitamin D receptor activator- paricalcitol. (4) Conclusions: In our study, we found that vitamin K deficiency, measured indirectly using the level of VKDP is associated to CKD-MBD. The use of medication such as phosphate binders, that reduce vitamin K absorbtion, Vitamin D that increases Vitamin K requirements and also vitamin K antagonists, seem to have an influence on the blood level of VKDPs.